CADTH Canadian drug expert committee recommendation : indication : for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexateUpadacitinib (Rinvoq -- abbVie)
The CADTH Canadian Drug Expert Committee (CDEC) recommends that upadacitinib be reimbursed for use as monotherapy or in combination with methotrexate or other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), if the following conditions are met : Conditions for Reimbursement, initiation Criteria 1. Adult patients with moderately to severely active RA on stable doses of disease-modifying antirheumatic drugs (DMARDs) who have had inadequate response or intolerance to methotrexate. 2. Upadacitinib should not be used in combination with other biologic DMARDs (bDMARDs) or Janus kinase (JAK) inhibitors..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
February 2020 |
|---|---|
| Erschienen: |
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health ; February 2020 |
| Ausgabe: |
Version: 1.0. |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Arthritis, Rheumatoid |
|---|
| Anmerkungen: |
"Final.". - Description based on online resource; title from PDF title page (viewed July 24, 2020) |
|---|
| Umfang: |
1 online resource (1 PDF file (9 pages)) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
177318525X |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 177318525X | ||
| 003 | DE-627 | ||
| 005 | 20230428011924.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211011s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)177318525X | ||
| 035 | |a (DE-599)KEP068717296 | ||
| 035 | |a (NCBI)1769356 | ||
| 035 | |a (EBP)068717296 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 110 | 2 | |a CADTH Canadian Drug Expert Committee, |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CADTH Canadian drug expert committee recommendation |b indication : for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexateUpadacitinib (Rinvoq -- abbVie) |
| 250 | |a Version: 1.0. | ||
| 264 | 1 | |a Ottawa (ON) |b Canadian Agency for Drugs and Technologies in Health |c February 2020 | |
| 300 | |a 1 online resource (1 PDF file (9 pages)) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a CADTH common drug review | |
| 500 | |a "Final.". - Description based on online resource; title from PDF title page (viewed July 24, 2020) | ||
| 520 | |a The CADTH Canadian Drug Expert Committee (CDEC) recommends that upadacitinib be reimbursed for use as monotherapy or in combination with methotrexate or other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), if the following conditions are met : Conditions for Reimbursement, initiation Criteria 1. Adult patients with moderately to severely active RA on stable doses of disease-modifying antirheumatic drugs (DMARDs) who have had inadequate response or intolerance to methotrexate. 2. Upadacitinib should not be used in combination with other biologic DMARDs (bDMARDs) or Janus kinase (JAK) inhibitors. | ||
| 650 | 2 | |a Arthritis, Rheumatoid |x drug therapy |0 https://id.nlm.nih.gov/mesh/D001172Q000188 | |
| 650 | 2 | |a Janus Kinase Inhibitors |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D000075242Q000627 | |
| 650 | 2 | |a Insurance, Health, Reimbursement |0 https://id.nlm.nih.gov/mesh/D007349 | |
| 651 | 2 | |a Canada |0 https://id.nlm.nih.gov/mesh/D002170 | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK558320/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 3994082315 |h h64 NCBI |y zi06404 |z 21-10-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 3994008565 |h OLR-NCB-BOOKSHELF |y xsn |z 21-10-21 | ||
| 980 | |2 74 |1 01 |x 0354 |b 3999784849 |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3995673422 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 25-10-21 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 3987674830 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-10-21 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 3987759747 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 11-10-21 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK558320/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK558320/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK558320/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK558320/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK558320/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||